InsidersTradesSigma
基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
无可用的信号评分。
Explore the full record of transactions filed by Sprague John M, 首席财务官. Director active across 1 company, notably T2 Biosystems, Inc.. Aggregated, 8 reports have been recorded. Breakdown: 1 buy · 0 sell. Total volume traded: €4k. Activity tracked since 8 April 2022. The latest transaction was disclosed on 8 April 2022 (Acquisition). Regulator: SEC (Form 4). All data is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 条申报中的 8 条
Sprague John M is Directeur Financier at T2 Biosystems, Inc. His 8 filings relate to T2 Biosystems, Inc., and, in the recent sample of 8 filings, they cover the period from 2022-02-23 to 2024-02-27, with EUR 4388 of buys and EUR 0 of sells. The most frequent transaction nature shown is Levée d'options.